Breaking News
Investing Pro 0
Black Friday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER

Should You Buy Eli Lilly Stock As Drugmaker Continues To Outperform Benchmarks?

By Haris Anwar/Investing.comStock MarketsSep 13, 2022 01:42PM ET
www.investing.com/analysis/should-you-buy-eli-lilly-stock-as-drugmaker-continues-to-outperform-benchmarks-200629768
Should You Buy Eli Lilly Stock As Drugmaker Continues To Outperform Benchmarks?
By Haris Anwar/Investing.com   |  Sep 13, 2022 01:42PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
LLY
+0.98%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
XLV
+0.59%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
  • Eli Lilly stock is looking expensive following its substantial gains in recent years
  • There are also some signs that sales are weakening due to the falling demand for COVID treatments and patent loss on its cancer drug
  • Despite these headwinds, LLY is a great long-term buy due to the company’s promising drug pipeline

Investors rushing to snap up safe bets amid the threat of a prolonged recession have propelled an impressive rally in Eli Lilly and Company's (NYSE:LLY) shares. The global drugmaker has seen its stock surge 31.6% during the past year, massively outperforming its peers.

LLY’s performance is even more impressive when compared to its benchmark ETF, the Health Care Select Sector SPDR® Fund (NYSE:XLV). While LLY stock rose to new highs in the past 12 months, XLV posted negative returns as cost pressures and supply chain hurdles hurt other drugmakers.

LLY, XLV, S&P 500 1-Year Price History
LLY, XLV, S&P 500 1-Year Price History

Source: InvestingPro

LLY stock, which has surged around three-fold during the past five years, may look expensive to some investors, especially when sales of the company’s COVID-19 antibody treatment are declining. Despite these headwinds, long-term investors have enough reasons to remain bullish on this name and take advantage of potential weaknesses in the coming days.

In the short term, Eli Lilly is facing some headwinds which could slow growth and hurt its stock. In its most recent earnings, the company reported that sales of its COVID-19 treatments fell 13% on declining demand for monoclonal antibody treatment, bebtelovimab. Such sales may continue to wipe out as the pandemic slowly enters an endemic stage with less buying interest from governments and individuals.

Another hit to Lilly’s sales is coming from the company’s cancer medicine Alimta, following the recent loss of U.S. patent exclusivity that allowed the introduction of competing, lower-cost generic copies and contributed to a 63% decline in sales for the branded product.

However, drugmakers face patent-related risks all the time. Thus, investors should favor companies with a robust pipeline of new drugs that could replace the diminishing sales of older drugs. Eli Lilly is undoubtedly one of those pharma giants that have done well on this front. 

$100 Billion Sales 

In a recent note to clients, Morgan Stanley named Eli Lilly one of the investment bank’s top picks for the next 12 months due to the company’s robust new product cycle outlook. The new launches from Lilly should bring in considerable sales, which will help boost the company’s top line, expand operating margins and lead to share growth. 

LLY Financial Health
src=

Source: InvestingPro

Bank of America expects Eli Lilly’s recently approved treatment for Type 2 diabetes, Mounjaro (or tirzepatide), could generate as much as $100 billion in annual sales by 2035--if it’s also approved to treat obesity and several other illnesses.

The bank, in a note last Friday, said:

“Of course, we recognize that Lilly’s ~30X P/E (2023) reflects optimism (peers: 11X), but its differentiated growth profile and pipeline progression still justifies putting money to work in shares at current levels, in our view,”

The Food and Drug Administration approved in May the weekly tirzepatide injection. However, the company is actively looking to use the drug to treat seven separate illnesses, including kidney disease and sleep apnea.

In addition, in June, Eli Lilly’s Alzheimer’s experimental drug donanemab gained breakthrough status from U.S. regulators, a designation that will speed its consideration for approval.

The drug now becomes the third to receive the designation based on its ability to attack amyloid, an abnormal protein believed to be involved in the damage Alzheimer’s causes in the brain. Lilly told investors last month that the Food and Drug Administration has accepted donanemab for review under an accelerated approval pathway.

Bottom Line

LLY has many catalysts for long-term growth that make its stock an attractive buy amid the current macro and geopolitical turmoil. 

Disclosure: The writer doesn’t own the shares of Eli Lilly nor XLV. 

Should You Buy Eli Lilly Stock As Drugmaker Continues To Outperform Benchmarks?
 

Related Articles

Should You Buy Eli Lilly Stock As Drugmaker Continues To Outperform Benchmarks?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email